SARS-CoV-2 Shedding Shows Huge Interindividual Variation
Clicks: 78
ID: 275535
2022
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
3.6
/100
12 views
12 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Significant disparities in the infective potential of SCOVID-19 patients have been observed in a study conducted at a university center. Providing possible insight into super-spreading events — a large population infected by a few individuals— the study provides a possible explanation of why such events play a disproportionately big role in the spread of the disease. In their study, from late 2020 to early 2021, during the advent of Alpha and other SARS-CoV-2 variants, 60 unvaccinated individuals with SARS-CoV-2 were identified by Christopher Brooke at the University of Illinois at Urbana– Champaign and his colleagues. For a fortnight, they collected daily samples from mild to asymptomatic patients. They found significant disparities in the number of days for which the patients shed viruses bearing infective potential: one discharged viable virus from the nose for nine days, while nine other patients did not shed any recognizable viruses capable of causing infection during the testing period. Estimates made via statistical modeling showed that the least infectious individuals shed viruses a staggering 57 times less than the most infectious individuals. Their findings reveal that viral RNA load maxed a few days after in the nose than in the saliva, and became untraceable approximately 14-21 days later. Nature Microbiol. 7, 640–652 (2022)
| Reference Key |
staff2022molecularsars-cov-2
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Editorial Staff; |
| Journal | Molecular Medicine Communications |
| Year | 2022 |
| DOI |
82
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.